Antibody-drug conjugates: Using IP and R&D Trends to Inform Innovation
VirtualSponsored by CAS (Chemical Abstracts Service) 10:00-11:00am, Online via Zoom, Free, Registration required Antibody-drug conjugates (ADCs) are among the most promising drug classes in oncology. The ADC research landscape is rapidly evolving, driven by advancements in antibody engineering, linker technology, payload development and diversification, and more. These new innovations are reshaping the promise of ADCs.. […]